NCPA aims to encourage independent pharmacies to adopt HIT
ALEXANDRIA, Va. An organization representing the country’s independent pharmacies will collaborate to encourage the adoption of health information technology.
The National Community Pharmacists Association said a conference at Alexandria, Va.’s Lorien Hotel Thursday was designed to ensure that community pharmacies are “working collaboratively” with partners to adopt HIT and take advantage of incentive programs, such as government stimulus money.
“Community pharmacies are committed to offering the best patient care possible, which means constantly adapting to the latest technology breakthroughs to optimize health care,” NCPA CEO and EVP Bruce Roberts said. “We recognize that health IT is part of that future, which is why we have launched technology-based products like Surescripts and Mirixa this decade.”
Senate to vote on drug importation measure
WASHINGTON U.S. Sen. Byron Dorgan, D-N.D., has dropped his proposal to add the importation of cheaper medicines from other countries to a tobacco legislation.
Dorgan claims that under the amendment, the Food and Drug Administration would be given the power to oversee packaging, marketing and manufacturing of cigarettes and other tobacco products, Reuters reported. Additionally, U.S.-licensed pharmacies and drug wholesalers would also be allowed to import FDA-approved medicines from Canada, Europe and a few other areas for cheaper prices.
The Senate will consider the drug issue separately, Reuters said.
President Barack Obama has asked Congress for $5 million for the FDA to get started. Despite presidental backing, drugmakers are unhappy with Dorgan’s bill, claiming that with importation comes the risk for counterfeit drugs.
The tobacco bill passed the Senate on Monday with a 61-30 vote and proceeds to legislation later this week.
KV Pharmaceuticals, Purdue Pharma settle OxyContin dispute
ST. LOUIS A generic drug company has settled a dispute with a branded drug company concerning the painkiller OxyContin.
St. Louis-based KV Pharmaceutical Co. announced Tuesday that it had entered a settlement agreement with Stamford, Conn.-based Purdue Pharma in a patent infringement lawsuit that Purdue filed against KV.
Under the terms of the agreement, KV agreed that Purdue’s patents for OxyContin (oxycodone hydrochloride) are valid, enforceable and infringed. In exchange, Purdue granted KV limited rights to sell generic controlled-release oxycodone hydrochloride tablets in the United States for an unspecified period of time.